BRAF and cancer: Progression‐free survival (PFS) is different between the cohorts, with dMMR/MSI‐H CRCs having a very favourable prognosis mainly due to the efficacy of immunotherapy and BRAF V600E mutant MSS cancers having a poor prognosis (Figure 1B).